matt krebs

@krebs_matt

Head of Asia Pacific Sales Operations . Post news, analysis and event updates from

California, USA
Vrijeme pridruživanja: studeni 2011.

Tweetovi

Blokirali ste korisnika/cu @krebs_matt

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @krebs_matt

  1. proslijedio/la je Tweet
    4. velj

    Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: . Meanwhile, at least 9 trials of #2019-nCoV therapies are underway. All BioCentury coverage of the outbreak is in front of the paywall at .

    Poništi
  2. proslijedio/la je Tweet
    2. velj

    Folks - is continuing to cover the outbreak, which is outside the paywall. This contains the therapeutic & preventive developments, policy actions, and biopharma response.

    Poništi
  3. 3. velj
    Poništi
  4. proslijedio/la je Tweet
    1. velj

    Approval of therapy huge step in right direction for food allergy patients, families, lends important validation to long-held theory that desensitization is effective to treat food allergies, writes 's

    Poništi
  5. proslijedio/la je Tweet
    30. sij

    W/ $45M series B led by Decheng, looks to capitalize on IP position around alternative enzyme, expand gene editing capabilities beyond Dx to therapeutic applications. 's talks w/ CEO Trevor Martin:

    Poništi
  6. 30. sij

    Arch backs Vizgen’s RNA imaging platform with $14M series A Vizgen is developing technology that will overcome capacity limitations of current single-cell RNA imaging technology? Details and analysis from s here:

    Poništi
  7. 30. sij

    Very cool newco backed by Flagship Pioneering. Details, analysis and insights in ’s Emerging Company Profiles here (subscription/ trial access required):

    Poništi
  8. 30. sij

    A+ for the Industry today! Biopharma leaders applaud CVS zero co-pay diabetes drug access Details here:

    Poništi
  9. proslijedio/la je Tweet
    28. sij

    Seeded by & Arix, debuts w/$50M series A to develop gasdermin D inhibitors for inflammatory diseases. 's speaks with CEO

    Poništi
  10. proslijedio/la je Tweet
    29. sij

    Had the pleasure of doing a Fireside Chat with at , and she is certainly moving the needle on this issue. Having a successful academic entrepreneur speak out is huge. A name to watch in all events.

    Poništi
  11. 28. sij

    HepaRegeniX aims to bring (first-in-class) liver program into clinic with €11M insider round Insights and analysis from 's here (subscription/trial access required):

    Poništi
  12. 28. sij

    MONEY RAISED IN 2020 Last week, the industry raised $2B. This brings YTD total to $5B. (Totals include overallotments and warrants, and are rounded to the nearest millions.) Wanna run your own analysis? Chk out

    Poništi
  13. 28. sij
    Poništi
  14. proslijedio/la je Tweet
    26. sij

    At least 8 #2019-nCoV vaccines under development using a variety of technologies. List below. In addition at least three groups are working on mAbs: Regeneron, Vir, and NIH’s NIAID. mAbs might be ready faster and provide both prophylaxis and treatment.

    Poništi
  15. 27. sij

    Was recently asked to look at at the innovative cos over past 5 year and their fund raising in Asia. Pulled up these charts so far. The data-set is limited to novel therapeutic cos. Want to do your own analysis? Details:

    Poništi
  16. proslijedio/la je Tweet
    25. sij

    Want to know who’s doing what to get CAR Ts to solid tumors? Winnie Pong has sliced and diced the data in . Take-home message: the majority are going after non-validated targets. Less of the lemming factor than in other areas of IO.

    Poništi
  17. 25. sij
    Poništi
  18. 23. sij

    This is from Dec, so not sure how I missed it. GREAT analysis from ‘s : A snapshot of where and how pharmas spin out their assets: (subscription/trial access required):

    Poništi
  19. proslijedio/la je Tweet
    22. sij

    Good story in last night on who's working on vaccines, diagnostics, & therapeutics for the coronavirus in the headlines incl: Moderna w/NIH, Novavax, US govt's VC firm In-Q-Tel, NY Blood Center, Baylor Medical School & more: by

    Prikaži ovu nit
    Poništi
  20. proslijedio/la je Tweet
    23. sij

    Disparities in FDA decisions on therapy raise Qs about integrity of review process. CDER's Ellis Unger, who rebuffed , had appealed Woodcock's approval of Exondys in 2016. 's reports:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·